EGFR and lymphangioma: Taken together, these results demonstrate that somatic mutations, particularly EGFR mutations, were more likely to be detected in CSF samples than in plasma samples, indicating that CSF samples are the optimal tumor DNA source for molecular testing in patients with LM.